NCT06379685View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 30, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Dry EyeDry Eyes ChronicDry Eye Syndromes
Interventions
DRUG

PRO-190

Propylene glycol 0.3% - Polyethylene glycol 400 0.3%. Ophthalmic solution.

DRUG

Systane Ultra®

Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.

All Listed Sponsors
lead

Laboratorios Sophia S.A de C.V.

INDUSTRY